Thanigaivelan Kanagasabai
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Prostatic Neoplasms | 5 | 2024 | 1092 | 0.890 |
Why?
|
| Sterol Regulatory Element Binding Protein 1 | 1 | 2021 | 12 | 0.710 |
Why?
|
| Insulin Receptor Substrate Proteins | 1 | 2021 | 23 | 0.700 |
Why?
|
| Proto-Oncogene Proteins c-mdm2 | 1 | 2019 | 39 | 0.610 |
Why?
|
| Imidazoles | 1 | 2019 | 142 | 0.590 |
Why?
|
| Piperazines | 1 | 2019 | 120 | 0.590 |
Why?
|
| Cell Proliferation | 6 | 2024 | 1455 | 0.580 |
Why?
|
| Angiogenesis Inhibitors | 2 | 2018 | 62 | 0.560 |
Why?
|
| Pyridinium Compounds | 1 | 2017 | 29 | 0.540 |
Why?
|
| Adenocarcinoma | 1 | 2019 | 291 | 0.510 |
Why?
|
| Indoles | 1 | 2017 | 187 | 0.480 |
Why?
|
| MicroRNAs | 1 | 2021 | 518 | 0.460 |
Why?
|
| Cell Movement | 2 | 2024 | 655 | 0.450 |
Why?
|
| S-Phase Kinase-Associated Proteins | 2 | 2024 | 23 | 0.430 |
Why?
|
| Killer Cells, Natural | 2 | 2025 | 104 | 0.420 |
Why?
|
| Jumonji Domain-Containing Histone Demethylases | 2 | 2024 | 12 | 0.380 |
Why?
|
| Apoptosis | 4 | 2024 | 1568 | 0.360 |
Why?
|
| Mice | 11 | 2025 | 6644 | 0.340 |
Why?
|
| Proto-Oncogene Proteins c-akt | 2 | 2024 | 299 | 0.320 |
Why?
|
| Cell Line, Tumor | 8 | 2025 | 2676 | 0.300 |
Why?
|
| Breast Neoplasms | 2 | 2018 | 1723 | 0.300 |
Why?
|
| Lung Neoplasms | 2 | 2024 | 495 | 0.290 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 2 | 2018 | 33 | 0.270 |
Why?
|
| Neovascularization, Pathologic | 2 | 2018 | 139 | 0.250 |
Why?
|
| Immunologic Surveillance | 1 | 2025 | 10 | 0.230 |
Why?
|
| Tumor Escape | 1 | 2025 | 17 | 0.230 |
Why?
|
| Animals | 11 | 2025 | 16992 | 0.220 |
Why?
|
| Signal Transduction | 3 | 2024 | 2157 | 0.220 |
Why?
|
| Pseudomonas | 1 | 2024 | 7 | 0.220 |
Why?
|
| Cytotoxicity, Immunologic | 1 | 2024 | 34 | 0.220 |
Why?
|
| Cell Communication | 1 | 2025 | 114 | 0.220 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2025 | 184 | 0.210 |
Why?
|
| Breast Neoplasms, Male | 1 | 2024 | 8 | 0.210 |
Why?
|
| Xenograft Model Antitumor Assays | 3 | 2024 | 347 | 0.210 |
Why?
|
| Receptors, Androgen | 1 | 2024 | 144 | 0.210 |
Why?
|
| Autophagy | 1 | 2024 | 140 | 0.200 |
Why?
|
| Disease Progression | 2 | 2024 | 667 | 0.190 |
Why?
|
| Nuclear Proteins | 2 | 2024 | 333 | 0.180 |
Why?
|
| Environmental Pollutants | 1 | 2024 | 201 | 0.180 |
Why?
|
| Acetyl-CoA Carboxylase | 1 | 2021 | 12 | 0.180 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2023 | 133 | 0.180 |
Why?
|
| Repressor Proteins | 2 | 2024 | 273 | 0.180 |
Why?
|
| Melanoma, Experimental | 1 | 2021 | 13 | 0.170 |
Why?
|
| Poly I-C | 1 | 2021 | 7 | 0.170 |
Why?
|
| Humans | 13 | 2025 | 43102 | 0.170 |
Why?
|
| Withanolides | 1 | 2021 | 10 | 0.170 |
Why?
|
| Male | 9 | 2024 | 23409 | 0.170 |
Why?
|
| Mitochondria | 1 | 2024 | 523 | 0.160 |
Why?
|
| Mice, Nude | 2 | 2021 | 408 | 0.160 |
Why?
|
| Mice, Knockout | 4 | 2025 | 1035 | 0.160 |
Why?
|
| CDC2 Protein Kinase | 1 | 2019 | 19 | 0.160 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2019 | 56 | 0.150 |
Why?
|
| Immunotherapy | 1 | 2021 | 144 | 0.150 |
Why?
|
| Biological Products | 1 | 2021 | 91 | 0.150 |
Why?
|
| Cell Cycle Proteins | 1 | 2021 | 241 | 0.150 |
Why?
|
| Mucin-1 | 1 | 2018 | 12 | 0.140 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2021 | 968 | 0.140 |
Why?
|
| Small Molecule Libraries | 1 | 2018 | 62 | 0.130 |
Why?
|
| Transcription Factors | 1 | 2021 | 735 | 0.120 |
Why?
|
| Mice, Inbred C57BL | 3 | 2025 | 1869 | 0.110 |
Why?
|
| Neoplasms | 1 | 2025 | 1377 | 0.110 |
Why?
|
| Antineoplastic Agents | 1 | 2017 | 1019 | 0.070 |
Why?
|
| Female | 4 | 2024 | 24698 | 0.070 |
Why?
|
| Monitoring, Immunologic | 1 | 2025 | 6 | 0.060 |
Why?
|
| Adoptive Transfer | 1 | 2025 | 53 | 0.060 |
Why?
|
| Receptors, Natural Killer Cell | 1 | 2024 | 4 | 0.060 |
Why?
|
| Biocatalysis | 1 | 2024 | 30 | 0.060 |
Why?
|
| Antigens, Neoplasm | 1 | 2025 | 90 | 0.060 |
Why?
|
| Lymphocyte Activation | 1 | 2025 | 249 | 0.050 |
Why?
|
| Biodegradation, Environmental | 1 | 2024 | 82 | 0.050 |
Why?
|
| Organ Specificity | 1 | 2024 | 141 | 0.050 |
Why?
|
| Metabolic Networks and Pathways | 1 | 2024 | 74 | 0.050 |
Why?
|
| Androgens | 1 | 2024 | 106 | 0.050 |
Why?
|
| Receptor, Adenosine A2B | 1 | 2023 | 5 | 0.050 |
Why?
|
| Memory Disorders | 1 | 2024 | 77 | 0.050 |
Why?
|
| Hepatocyte Nuclear Factor 3-alpha | 1 | 2023 | 6 | 0.050 |
Why?
|
| Phosphates | 1 | 2023 | 54 | 0.050 |
Why?
|
| Immunity, Innate | 1 | 2024 | 171 | 0.050 |
Why?
|
| Proliferating Cell Nuclear Antigen | 1 | 2023 | 47 | 0.050 |
Why?
|
| Adenosine | 1 | 2023 | 62 | 0.050 |
Why?
|
| Mitochondrial Proteins | 1 | 2024 | 118 | 0.050 |
Why?
|
| Ubiquitination | 1 | 2023 | 62 | 0.050 |
Why?
|
| Lysosomes | 1 | 2023 | 86 | 0.050 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2024 | 223 | 0.050 |
Why?
|
| Astrocytes | 1 | 2024 | 244 | 0.050 |
Why?
|
| Interferon Inducers | 1 | 2021 | 2 | 0.040 |
Why?
|
| Hippocampus | 1 | 2024 | 594 | 0.040 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2021 | 49 | 0.040 |
Why?
|
| Incidence | 1 | 2024 | 1078 | 0.040 |
Why?
|
| Drug Therapy, Combination | 1 | 2021 | 234 | 0.040 |
Why?
|
| Membrane Proteins | 1 | 2024 | 561 | 0.040 |
Why?
|
| Kidney Neoplasms | 1 | 2021 | 80 | 0.040 |
Why?
|
| Tumor Cells, Cultured | 1 | 2021 | 508 | 0.040 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2021 | 134 | 0.040 |
Why?
|
| Mice, Inbred BALB C | 1 | 2021 | 694 | 0.040 |
Why?
|
| Inflammation | 1 | 2024 | 758 | 0.040 |
Why?
|
| Laminin | 1 | 2018 | 58 | 0.030 |
Why?
|
| Proteoglycans | 1 | 2018 | 49 | 0.030 |
Why?
|
| Drug Combinations | 1 | 2018 | 104 | 0.030 |
Why?
|
| Collagen | 1 | 2018 | 181 | 0.030 |
Why?
|
| DNA-Binding Proteins | 1 | 2020 | 561 | 0.030 |
Why?
|
| Brain | 1 | 2024 | 1472 | 0.030 |
Why?
|
| Risk Factors | 1 | 2024 | 3994 | 0.030 |
Why?
|